Methylnaltrexone

證據等級: L5

預測適應症: 10 個

Methylnaltrexone: Predicted New Indication — Congenital Hypotrichosis Milia (Original Indication Not Available)

One-Sentence Summary

Methylnaltrexone’s original indication and mechanism of action are not documented in the current evidence pack, and the drug is not currently registered for supply in Australia (0 ARTG entries). The TxGNN model’s top-ranked prediction is Congenital Hypotrichosis Milia (score 78.35%), but this candidate has no supporting clinical trials or literature, and the evidence pack itself flags it as a low-confidence model artefact with no plausible mechanistic link.

Quick Overview

Item	Content
Original Indication	Not documented in the evidence pack (no ARTG entries or original-indication data available)
Predicted New Indication	Congenital Hypotrichosis Milia
TxGNN Prediction Score	78.35%
Evidence Level	L5
Australia Market Status	Not Marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data for methylnaltrexone is not available in this evidence pack. Based on known pharmacology, methylnaltrexone is a peripherally restricted µ-opioid receptor antagonist class agent, but no original indication is recorded here to anchor a mechanistic comparison.

For the top-ranked prediction, congenital hypotrichosis milia, the evidence pack’s own rationale states there is no known pathophysiological connection to peripheral µ-opioid receptor antagonism — this is a congenital hereditary hair-development disorder, and the pairing is assessed as a pure model prediction with no supporting mechanistic hypothesis.

It is worth noting that lower-ranked candidates in this pack carry more plausible biological rationale than the top-ranked one: respiratory failure (rank 7, evidence level L4) has a partial mechanistic argument around peripheral µ1-receptor involvement in opioid-induced cardiorespiratory depression, and alopecia (rank 5) references literature suggesting hair follicles express opioid receptors. Neither, however, has clinical trial or robust literature support at this time.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available for Congenital Hypotrichosis Milia.

Note: the pack does contain 2 literature records under the lower-ranked “respiratory failure” candidate (rank 7): 21164413 (2010, general ICU review) and 41087032 (2025, review on peripheral/central µ1-receptor roles in fentanyl-induced cardiorespiratory responses) — neither is a direct efficacy study.

Australia Market Information

Methylnaltrexone is not currently registered in the Australian Register of Therapeutic Goods (0 ARTG entries recorded).

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction (congenital hypotrichosis milia) is evidence level L5 — a model-only prediction with no clinical trials, no literature, and no biologically plausible mechanism per the evidence pack’s own assessment. Combined with the absence of Australian registration and unresolved blocking safety data gaps, there is no basis to progress this candidate.

To proceed, the following is needed:

TGA Product Information warnings/contraindications (flagged as a Blocking data gap — required before any S1 safety screening)
Confirmed mechanism of action data from DrugBank (flagged as a High-severity gap affecting mechanistic assessment)
Original indication and regulatory history for methylnaltrexone, currently absent from this pack
If further repurposing work continues, prioritise the more mechanistically grounded candidates already surfaced in this pack — respiratory failure (L4/S1, “Research Question”) and alopecia — over the top-ranked but mechanistically unsupported prediction
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.